DK3210973T3 - HETEROARYL COMPOUNDS FOR THE TREATMENT OF Ophthalmic Diseases - Google Patents
HETEROARYL COMPOUNDS FOR THE TREATMENT OF Ophthalmic Diseases Download PDFInfo
- Publication number
- DK3210973T3 DK3210973T3 DK15853151.7T DK15853151T DK3210973T3 DK 3210973 T3 DK3210973 T3 DK 3210973T3 DK 15853151 T DK15853151 T DK 15853151T DK 3210973 T3 DK3210973 T3 DK 3210973T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- ophthalmic diseases
- heteroaryl compounds
- heteroaryl
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/46—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014217770 | 2014-10-24 | ||
PCT/JP2015/079782 WO2016063933A1 (en) | 2014-10-24 | 2015-10-22 | Heterocyclic compound |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3210973T3 true DK3210973T3 (en) | 2021-02-08 |
Family
ID=55760964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15853151.7T DK3210973T3 (en) | 2014-10-24 | 2015-10-22 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF Ophthalmic Diseases |
Country Status (37)
Country | Link |
---|---|
US (4) | US10214498B2 (en) |
EP (2) | EP3848353A1 (en) |
JP (2) | JP6588027B2 (en) |
KR (1) | KR102490156B1 (en) |
CN (2) | CN107108506B (en) |
AR (1) | AR104342A1 (en) |
AU (2) | AU2015336480B2 (en) |
BR (1) | BR112017007138A2 (en) |
CA (1) | CA2965465C (en) |
CL (1) | CL2017000944A1 (en) |
CO (1) | CO2017003699A2 (en) |
CR (1) | CR20170160A (en) |
CY (1) | CY1123842T1 (en) |
DK (1) | DK3210973T3 (en) |
DO (1) | DOP2017000098A (en) |
EA (1) | EA033446B1 (en) |
EC (1) | ECSP17026687A (en) |
ES (1) | ES2848999T3 (en) |
HR (1) | HRP20210320T1 (en) |
HU (1) | HUE053443T2 (en) |
IL (2) | IL285105B2 (en) |
LT (1) | LT3210973T (en) |
MA (2) | MA39688B1 (en) |
MX (2) | MX2017004629A (en) |
MY (1) | MY183209A (en) |
PE (1) | PE20170669A1 (en) |
PH (1) | PH12017500747B1 (en) |
PL (1) | PL3210973T3 (en) |
PT (1) | PT3210973T (en) |
RS (1) | RS61504B1 (en) |
SG (1) | SG11201702312UA (en) |
SI (1) | SI3210973T1 (en) |
TN (1) | TN2017000097A1 (en) |
TW (2) | TWI749661B (en) |
UA (1) | UA121871C2 (en) |
WO (1) | WO2016063933A1 (en) |
ZA (1) | ZA201703344B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA033446B1 (en) * | 2014-10-24 | 2019-10-31 | Takeda Pharmaceuticals Co | Heterocyclic compound for treating macular degeneration and/or stargardt's disease |
JP7306997B2 (en) | 2017-03-20 | 2023-07-11 | ザ・ブロード・インスティテュート・インコーポレイテッド | Compounds and methods for the treatment of parasitic diseases |
TW201904968A (en) | 2017-06-15 | 2019-02-01 | 開曼群島商貝利特生物股份有限公司 | Method for treating RBP4-related diseases with triazolopyridine |
WO2020028723A1 (en) * | 2018-08-01 | 2020-02-06 | The Trustees Of Columbia University In The City Of New York | Rbp4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout |
CN111690695A (en) * | 2020-05-19 | 2020-09-22 | 浙江工业大学 | Enzymatic microfluidic online synthesis method of 3-phenylaminopropylhydroxamic acid |
CN111690698A (en) * | 2020-05-19 | 2020-09-22 | 浙江工业大学 | Method for synthesizing 3- (benzo [ d ] [1,3] dioxo-5-amino) propyl hydroxamic acid by two-step serial flow |
WO2022256301A1 (en) * | 2021-06-01 | 2022-12-08 | Stargazer Pharmaceuticals, Inc. | Methods and compounds for treating subjects with stargardt disease |
CN116286900B (en) * | 2022-10-28 | 2024-04-26 | 昆明理工大学 | Acetic acid permease A gene RkAcpa and application thereof |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3625970A (en) | 1968-04-17 | 1971-12-07 | Cutter Lab | 1-(disubstituted phenyl or benzyl)-1h-indazol-3-yloxyacetic acid |
US5239080A (en) | 1989-02-08 | 1993-08-24 | Takeda Chemical Industries, Ltd. | Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents |
EP0440183A1 (en) * | 1990-02-01 | 1991-08-07 | Takeda Chemical Industries, Ltd. | Oxazole compounds, their production and use |
US6025372A (en) | 1997-04-04 | 2000-02-15 | Merck & Co., Inc. | Somatostatin agonists |
US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
WO1999022735A1 (en) | 1997-10-30 | 1999-05-14 | Merck & Co., Inc. | Somatostatin agonists |
AR035016A1 (en) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | COMPOSITION OF AZOL PROMOTER OF PRODUCTION / SECRETION OF NEUROTROFINE, COMPOSITE PRODROGA OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THE SAME TO PREPARE THIS LAST. |
WO2001025228A1 (en) | 1999-10-07 | 2001-04-12 | Tadeka Chemical Industries, Ltd. | Amine derivatives |
PL356487A1 (en) | 1999-11-10 | 2004-06-28 | Takeda Chemical Industries, Ltd. | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
GB0020351D0 (en) | 2000-08-17 | 2000-10-04 | Catalyst Biomedica Ltd | Treatment of hyperproliferative diseases |
DE10149568A1 (en) | 2001-10-08 | 2003-04-24 | Consequence Gmbh | Detection of amines, especially aminoacids formed in sequencing of peptides by Edman degradation, by forming reaction product with halo-substituted phenylisothiocyanate |
WO2003042204A1 (en) | 2001-10-19 | 2003-05-22 | Takeda Chemical Industries, Ltd. | Amine derivative |
US20040214788A1 (en) | 2003-03-11 | 2004-10-28 | Raj Madhwa H.G. | Treatment of prostate cancer |
AR043633A1 (en) | 2003-03-20 | 2005-08-03 | Schering Corp | CANABINOID RECEIVERS LINKS |
WO2005019184A1 (en) | 2003-08-20 | 2005-03-03 | Eli Lilly And Company | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
EP1692521A1 (en) | 2003-12-11 | 2006-08-23 | Beth Israel Deaconess Medical Center, Inc. | Rbp4 in insulin sensitivity/resistance, diabetes, and obesity |
US7838561B2 (en) | 2004-06-14 | 2010-11-23 | Wisconsin Alumni Research Foundation | Method for preventing or treating cardiac hypertrophy |
NZ551955A (en) | 2004-06-23 | 2010-08-27 | Revision Therapeutics Inc | Methods and compositions for treating ophthalmic conditions with retinyl derivatives |
US20080033053A1 (en) | 2004-07-22 | 2008-02-07 | Wolfgang Curt D | Cross-Reference To Related Applications |
US7947267B2 (en) | 2004-10-08 | 2011-05-24 | Potentia Pharmaceuticals, Inc. | Viral complement control proteins for eye disorders |
CA2655036A1 (en) | 2006-06-22 | 2007-12-27 | Sirion Therapeutics, Inc. | Methods and compositions for treating ophthalmic conditions via modulation of megalin activity |
AU2008268409B2 (en) | 2007-06-26 | 2013-12-05 | Lexicon Pharmaceuticals, Inc. | Compositions comprising tryptophan hydroxylase inhibitors |
MX2009013990A (en) | 2007-06-26 | 2010-03-30 | Lexicon Pharmaceuticals Inc | Methods of treating serotonin-mediated diseases and disorders. |
US7973079B2 (en) | 2007-09-27 | 2011-07-05 | Revision Therapeutics, Inc. | Methods and compounds for treating retinol-related diseases |
WO2009042444A2 (en) | 2007-09-27 | 2009-04-02 | Sirion Therapeutics, Inc. | Methods and compounds for treating retinol-related diseases |
US8586571B2 (en) | 2007-10-18 | 2013-11-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2009143390A2 (en) | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc. | Methods for modulating expression of rbp4 |
WO2009145286A1 (en) | 2008-05-30 | 2009-12-03 | 武田薬品工業株式会社 | Heterocyclic compound |
KR20120022927A (en) * | 2009-04-13 | 2012-03-12 | 아이알엠 엘엘씨 | Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4) |
KR20120006545A (en) * | 2009-04-16 | 2012-01-18 | 다케다 야쿠힌 고교 가부시키가이샤 | Derivatives of n-acyl-n'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes |
WO2011059776A2 (en) | 2009-10-28 | 2011-05-19 | Revision Therapeutics, Inc | Prophylaxis of skin cancer with retinamides |
CA2781888C (en) | 2009-12-11 | 2019-06-18 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
KR101955691B1 (en) | 2010-03-30 | 2019-03-07 | 베르선 코포레이션 | Multisubstituted aromatic compounds as inhibitors of thrombin |
US8980924B2 (en) | 2010-11-24 | 2015-03-17 | The Trustees Of Columbia University In The City Of New York | Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease |
DK2707101T3 (en) | 2011-05-12 | 2019-05-13 | Proteostasis Therapeutics Inc | PROTEOSTASE REGULATORS |
GB201205679D0 (en) | 2012-03-30 | 2012-05-16 | Dyson Technology Ltd | A hand held appliance |
WO2013166041A1 (en) | 2012-05-01 | 2013-11-07 | The Trustees Of Columbia University In The City Of New York | Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular |
WO2014134127A1 (en) | 2013-02-26 | 2014-09-04 | Northeastern University | Cannabinergic nitrate esters and related analogs |
WO2014160409A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of Columbia University In The City Of New York | Rbp4 antagonists for the treatment of age-related macular degeneration and stargardt disease |
WO2014153643A1 (en) | 2013-03-26 | 2014-10-02 | The University Of British Columbia | Compositions and methods for use thereof in the treatment of aniridia |
CN106458856A (en) | 2014-03-07 | 2017-02-22 | 约翰霍普金斯大学 | Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs) |
TN2017000158A1 (en) | 2014-10-24 | 2018-10-19 | Bristol Myers Squibb Co | Carbazole derivatives |
EA033446B1 (en) * | 2014-10-24 | 2019-10-31 | Takeda Pharmaceuticals Co | Heterocyclic compound for treating macular degeneration and/or stargardt's disease |
SI3461821T1 (en) | 2014-10-24 | 2020-09-30 | Bristol-Myers Squibb Company | Indole carboxamide compounds useful as kinase inhibitors |
US11040976B2 (en) | 2015-04-24 | 2021-06-22 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof |
US10189797B2 (en) | 2015-12-30 | 2019-01-29 | Duke University | Chemical modulators of immune checkpoints and therapeutic use |
-
2015
- 2015-10-22 EA EA201790912A patent/EA033446B1/en unknown
- 2015-10-22 EP EP20210993.0A patent/EP3848353A1/en active Pending
- 2015-10-22 MX MX2017004629A patent/MX2017004629A/en unknown
- 2015-10-22 MA MA39688A patent/MA39688B1/en unknown
- 2015-10-22 MA MA053568A patent/MA53568A/en unknown
- 2015-10-22 IL IL285105A patent/IL285105B2/en unknown
- 2015-10-22 UA UAA201705014A patent/UA121871C2/en unknown
- 2015-10-22 JP JP2016555273A patent/JP6588027B2/en not_active Expired - Fee Related
- 2015-10-22 CR CR20170160A patent/CR20170160A/en unknown
- 2015-10-22 TN TN2017000097A patent/TN2017000097A1/en unknown
- 2015-10-22 PL PL15853151T patent/PL3210973T3/en unknown
- 2015-10-22 DK DK15853151.7T patent/DK3210973T3/en active
- 2015-10-22 CA CA2965465A patent/CA2965465C/en active Active
- 2015-10-22 HU HUE15853151A patent/HUE053443T2/en unknown
- 2015-10-22 PT PT158531517T patent/PT3210973T/en unknown
- 2015-10-22 CN CN201580057721.9A patent/CN107108506B/en active Active
- 2015-10-22 WO PCT/JP2015/079782 patent/WO2016063933A1/en active Application Filing
- 2015-10-22 US US15/517,227 patent/US10214498B2/en active Active
- 2015-10-22 EP EP15853151.7A patent/EP3210973B1/en active Active
- 2015-10-22 MY MYPI2017701205A patent/MY183209A/en unknown
- 2015-10-22 KR KR1020177011195A patent/KR102490156B1/en active IP Right Grant
- 2015-10-22 SI SI201531515T patent/SI3210973T1/en unknown
- 2015-10-22 BR BR112017007138A patent/BR112017007138A2/en not_active Application Discontinuation
- 2015-10-22 PE PE2017000713A patent/PE20170669A1/en unknown
- 2015-10-22 CN CN202210625914.1A patent/CN115197160A/en active Pending
- 2015-10-22 LT LTEP15853151.7T patent/LT3210973T/en unknown
- 2015-10-22 RS RS20210236A patent/RS61504B1/en unknown
- 2015-10-22 SG SG11201702312UA patent/SG11201702312UA/en unknown
- 2015-10-22 ES ES15853151T patent/ES2848999T3/en active Active
- 2015-10-22 AU AU2015336480A patent/AU2015336480B2/en not_active Ceased
-
2016
- 2016-04-21 TW TW109124954A patent/TWI749661B/en active
- 2016-04-21 TW TW105112410A patent/TWI703131B/en not_active IP Right Cessation
- 2016-04-21 AR ARP160101102A patent/AR104342A1/en unknown
-
2017
- 2017-04-07 MX MX2021001188A patent/MX2021001188A/en unknown
- 2017-04-12 IL IL251695A patent/IL251695B/en unknown
- 2017-04-17 CL CL2017000944A patent/CL2017000944A1/en unknown
- 2017-04-18 CO CONC2017/0003699A patent/CO2017003699A2/en unknown
- 2017-04-19 DO DO2017000098A patent/DOP2017000098A/en unknown
- 2017-04-21 PH PH12017500747A patent/PH12017500747B1/en unknown
- 2017-04-28 EC ECIEPI201726687A patent/ECSP17026687A/en unknown
- 2017-05-15 ZA ZA2017/03344A patent/ZA201703344B/en unknown
-
2018
- 2018-12-21 US US16/230,634 patent/US10544111B2/en not_active Expired - Fee Related
-
2019
- 2019-09-11 JP JP2019165717A patent/JP6995094B2/en active Active
-
2020
- 2020-01-27 US US16/773,720 patent/US10975043B2/en active Active
- 2020-07-02 AU AU2020204426A patent/AU2020204426B2/en not_active Ceased
-
2021
- 2021-02-23 CY CY20211100152T patent/CY1123842T1/en unknown
- 2021-02-25 HR HRP20210320TT patent/HRP20210320T1/en unknown
- 2021-04-09 US US17/226,854 patent/US20210340114A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3212233T3 (en) | COMBINATION THERAPY FOR TREATMENT OF DISEASE | |
DK3245206T3 (en) | Pyrazine compounds for the treatment of infectious diseases | |
DK3728271T3 (en) | Macrocyclic compounds for the treatment of diseases | |
DK3240612T3 (en) | PROCEDURES FOR THE TREATMENT OF RHINTH DISEASES | |
DK3173092T3 (en) | RNA-Containing Composition for the Treatment of Tumor Diseases | |
DK3192902T3 (en) | PROCEDURE FOR THE MANUFACTURE OF GRAPHENCY VISCOSEFIBREES | |
DK3492632T3 (en) | METHODS FOR THE TREATMENT OF LITHIUM-CONTAINING MATERIALS | |
DK3134530T3 (en) | TREATMENT OF HYPERBILIR RUBINY | |
DK3125875T3 (en) | INHALABLE RAPAMYCINFORMULATION FOR THE TREATMENT OF AGING-RELATED CONDITIONS | |
DK3096741T3 (en) | PROCEDURE FOR THE PREPARATION OF HYBRIDOSOMES | |
DK3390390T3 (en) | Bipyrazolyl derivatives suitable for the treatment of autoimmune diseases | |
DK3148529T3 (en) | COMPOUNDS FOR THE TREATMENT OF BRAIN CANCER | |
DK3174858T3 (en) | PROCEDURE FOR THE PREPARATION OF PYRAZOLS | |
DK3169328T3 (en) | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATION DISEASES | |
DK3362066T3 (en) | COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES | |
DK3204398T3 (en) | PROCEDURES FOR PHARMACEUTICAL PREPARATION OF GEMCITABIN-PHOSPHATE DIASTEREOISOMER | |
DK3157534T3 (en) | ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS | |
DK3210973T3 (en) | HETEROARYL COMPOUNDS FOR THE TREATMENT OF Ophthalmic Diseases | |
DK3498278T3 (en) | Compounds for the treatment of diseases related to DUX4 expression | |
DK3233813T3 (en) | PROCEDURES FOR THE PREPARATION OF OXATHIAZINE-LIKE COMPOUNDS | |
DK3164394T3 (en) | GLS1 INHIBITORS FOR TREATMENT OF DISEASES | |
DK3430143T3 (en) | Inhibitors of SRSF1 for the treatment of neurodegenerative diseases | |
DK3097085T3 (en) | BENZOXAZINE DERIVATIVES FOR THE TREATMENT OF SKIN DISEASES | |
DK3578562T3 (en) | L-VALINATAMIDE BENZOXABOROL DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | |
DK3164716T3 (en) | PROCEDURE FOR DIAGNOSTICING NEURODEGENERATIVE DISEASES |